Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7275MR)

This product GTTS-WQ7275MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7275MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6720MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ7250MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ12239MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ7958MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ7655MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ14480MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ12532MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ4439MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW